Hungarian Drug Prices Rise 12% This Month

20 January 1997

Hungary's Welfare Ministry has announced that medicine prices will riseby an average of 12% in the middle of January, reports MTI Econews. Drug prices increased 35% on average in Hungary during 1996, with Health Insurance Fund subsidies on retail drug prices totaling 81.85 billion forint ($503.7 million) in the year.

Current price subsidies are to remain unchanged, but new, tighter regulations, to be drawn up by end-March, will be introduced on the prescribing of antidepressants and antibiotics. The system of drug price subsidies could be changed in the second half of 1997, when stricter controls will be introduced on the issuing of prescriptions.

Around 20% of all Hungarian drug price subsidies go on providing free medicines to people on low incomes. The average annual subsidy per person is 7,200 forint, and the average spent on those entitled to free medicines (whose numbers rose from 300,000 in 1995 to 550,000 in 1996) is 26,781 forint.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight